Affordable Access

deepdyve-link
Publisher Website

[Regional state-of-the-art of the access to oncofertility consultation for young women with breast cancer].

Authors
  • Gosset, A1
  • Cohade, C1
  • Grosclaude, P2
  • Oumsack, E3
  • Dalenc, F4
  • Montagut, M5
  • Parinaud, J1
  • Vaysse, C6
  • 1 Département de médecine de la reproduction, CHU de Toulouse, 330, avenue de Grande Bretagne, TSA 70034, 31059 Toulouse, France. , (France)
  • 2 Registre des cancers du Tarn, institut Claudius-Regaud, institut universitaire du cancer de Toulouse-Oncopole, 31059 Toulouse, France; Inserm, UMR1027, université de Toulouse, université Paul-Sabatier, 31000 Toulouse, France. , (France)
  • 3 Registre des cancers du Tarn, institut Claudius-Regaud, institut universitaire du cancer de Toulouse-Oncopole, 31059 Toulouse, France. , (France)
  • 4 Département d'oncologie médicale, institut Claudius-Regaud, institut universitaire du cancer de Toulouse-Oncopole, 1, avenue Irène-Joliot-Curie, 31059 Toulouse cedex 9, France. , (France)
  • 5 Service d'assistance médicale à la procréation, Clinique Croix du Sud, 20, route de Revel, 31000 Toulouse, France. , (France)
  • 6 Département de chirurgie gynécologique et oncologique, institut universitaire du cancer de Toulouse-Oncopole, CHU deToulouse, 1, avenue Irène-Joliot-Curie, 31059 Toulouse cedex 9, France. Electronic address: [email protected] , (France)
Type
Published Article
Journal
Gynecologie, obstetrique, fertilite & senologie
Publication Date
Oct 01, 2019
Volume
47
Issue
10
Pages
732–738
Identifiers
DOI: 10.1016/j.gofs.2019.08.005
PMID: 31493561
Source
Medline
Keywords
Language
French
License
Unknown

Abstract

According to the 2004 Bioethics Act, oncofertility counselling must be systematically offered to all women of childbearing age before they are exposed to potentially gonadotoxic treatment. The main objective of this study was to evaluate the proportion of women under 40 years of age treated with chemotherapy for breast cancer in Midi-Pyrénées who have received an oncofertility consultation. A secondary objective was to assess practitioners' knowledge on the subject. A cross-reference was made between the databases of the oncology network in Midi-Pyrénées and the two approved centres for the preservation of fertility in the region. A computerized practitioner questionnaire was sent to all surgeons and oncologists who could manage these patients. From 2012 and 2017, 667 women aged≤40 years received (neo)adjuvant chemotherapy treatment: only 156 (23.4%) had access to an oncofertility consultation and 58 (8.7%) received preservation. This rate (23.4%) varied according to the age of the patients, ranging from 56.9% for those aged 25-29 to 13.4% for those aged 35-39 and the managing institution. Of the 85 practitioners surveyed, 45 (55%) responded to the questionnaire, and of these 20 (44%) knew that ovarian stimulation treatment could be used even in hormone-dependent breast cancer situations and 13 (29%) of practitioners believed that the time required to preserve fertility was more than 1 month. Our study revealed a significant disparity in access to oncofertility consultation. It is essential to set up information and awareness-raising actions on the subject. Copyright © 2019 Elsevier Masson SAS. All rights reserved.

Report this publication

Statistics

Seen <100 times